Mecobalamin - Eisai

Drug Profile

Mecobalamin - Eisai

Alternative Names: E 0302

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eisai Co Ltd
  • Class Vitamin B12 analogues; Vitamins
  • Mechanism of Action Methyltransferase stimulants; Vitamin B12 receptor protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis

Most Recent Events

  • 02 Aug 2017 Discontinued - Preregistration for Amyotrophic lateral sclerosis in Japan (IM), because mecobalamin was not listed on Eisai pipeline of August 2017
  • 31 Mar 2017 Eisai completes a phase II/III extension trial for Amyotrophic lateral sclerosis in Japan (IM) (NCT00445172)
  • 22 Mar 2016 Eisai withdraws NDA for Amyotrophic lateral sclerosis (ALS) in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top